knock
express
diseaserel
gene
use
small
interf
rna
sirna
potenti
treat
varieti
ill
essay
examin
opportun
har
rna
interfer
rnai
therapi
well
obstacl
possibl
way
circumv
five
year
ago
tuschl
colleagu
show
rna
interfer
rnai
work
mammalian
cell
found
endogen
rnai
pathway
har
introduc
small
doublestrand
rna
compris
nucleotid
complementari
sequenc
call
small
interf
rna
sirna
mammalian
cell
silenc
gene
express
exquisit
specif
without
activ
interferon
respons
elbashir
et
al
translat
research
quick
realiz
potenti
use
rnai
identifi
new
drug
target
design
small
molecul
drug
sirnabas
drug
develop
proceed
dizzi
pace
first
demonstr
diseas
protect
use
sirna
mous
model
publish
three
year
ago
song
et
al
human
safeti
clinic
studi
began
littl
year
later
well
much
basic
phenomena
rnai
realli
understood
believ
agre
sirna
potenti
becom
next
new
class
drug
three
phase
clinic
studi
investig
sirna
treat
agerel
macular
degener
respiratori
syncyti
viru
rsv
infect
complet
report
untoward
toxic
abil
design
sirna
host
gene
pathogen
genet
sequenc
known
test
rapidli
highlight
key
advantag
sirna
drug
develop
compar
convent
small
molecul
drug
exampl
human
phase
studi
sirna
target
rsv
alnylam
began
month
compani
start
work
project
de
fougerol
person
commun
origin
rnai
studi
gene
express
silenc
transduc
cultur
mammalian
cell
line
sirna
viral
vector
encod
short
hairpin
rna
shrna
process
within
cell
like
endogen
microrna
two
approachessirna
small
molecul
drug
shrna
gene
therapyar
two
pathway
avail
har
rnai
research
develop
therapeut
gene
therapi
applic
rnai
like
remain
mostli
academ
exercis
immedi
futur
earli
clinic
studi
focus
use
sirna
small
molecul
drug
howev
discuss
essay
mani
hurdl
overcom
sirna
drug
becom
realiti
use
drug
sirna
need
deliv
vivo
cytoplasm
cell
rnainduc
silenc
complex
risc
take
doublestrand
sirna
cleav
sens
passeng
strand
leav
activ
risc
contain
antisens
strand
search
mrna
contain
complementari
sequenc
small
interf
rna
introduc
cytoplasm
taken
risc
strand
whose
less
tightli
bound
incorpor
activ
guid
strand
wherea
strand
passeng
strand
cleav
activ
risc
recogn
target
mrna
bear
complementari
sequenc
cleav
target
mrna
cleav
risc
recycl
seek
destroy
anoth
mrna
potenc
sirna
drug
link
incorpor
stabil
endogen
risc
complex
present
cell
catalyt
natur
cleavag
reaction
target
degrad
figur
although
sirna
readili
taken
invertebr
cell
sirna
taken
mammalian
cell
way
preserv
activ
even
cell
activ
sampl
environ
dendrit
cell
macrophag
take
sirna
effici
enough
activ
gene
silenc
although
lipidbas
transfect
introduc
sirna
varieti
cell
vitro
mani
import
cell
primari
lymphocyt
hematopoiet
stem
cell
refractori
transfect
although
nucleofect
proprietari
electropor
method
develop
amaxa
work
cell
moreov
method
intracellular
deliveri
suitabl
vivo
use
therefor
sirna
intracellular
deliveri
formid
obstacl
sirna
drug
develop
practic
solut
deliveri
problem
howev
becom
avail
tissu
bodi
easili
access
includ
respiratori
genit
tract
eye
take
sirna
topic
applic
direct
inject
nake
sirna
alon
complex
cation
lipid
use
vitro
transfect
bitko
et
al
pallis
et
al
phase
clinic
studi
treat
agerel
macular
degener
retina
rsv
respiratori
tract
demonstr
uptak
target
tissu
intravitr
inject
intranas
applic
nake
sirna
respect
cell
epithelium
lamina
propria
mous
vagina
cervix
effici
take
sirnalipid
complex
may
well
cell
mucos
surfac
bodi
effici
intern
sirna
suggest
topic
sirna
therapi
fewest
hurdl
overcom
given
mucos
surfac
portal
entri
pathogen
use
topic
appli
sirna
prevent
treat
intracellular
infect
attract
option
especi
viral
infect
drug
exist
exampl
local
sirna
deliveri
lung
abl
protect
nonhuman
primat
infect
sar
coronaviru
li
et
al
opportun
local
treatment
includ
local
inflammatori
diseas
season
rhiniti
mucos
malign
cancer
head
neck
nasopharynx
cervix
caus
transform
virus
provid
specif
gene
target
target
inflammatori
lung
diseas
asthma
also
high
agenda
least
one
rnai
biotechnolog
compani
requir
aerosol
deliveri
introduc
sirna
appropri
epitheli
immun
cell
deep
within
lung
howev
still
clear
primari
cell
type
access
tissu
effici
take
nake
sirna
sirnalipid
complex
would
amen
local
sirna
therapeut
deliveri
moreov
mechan
uptak
mammalian
cell
understood
answer
question
import
choos
best
diseas
target
rnai
therapeut
earliest
studi
show
sirna
effect
system
anim
diseas
model
reli
hydrodynam
inject
techniqu
sirna
inject
rapidli
larg
bolu
caus
transient
damag
cell
membran
highli
vascular
organ
enabl
sirna
access
cytoplasm
mccaffrey
et
al
song
et
al
method
inject
danger
feasibl
human
use
howev
catheter
vein
drain
organ
possibl
rais
vascular
pressur
local
introduc
sirna
therapeut
benefici
hamar
et
al
earli
studi
suggest
nake
sirna
would
intern
convent
intraven
inject
tissu
howev
sensit
detail
tissu
survey
never
use
drug
sirna
top
must
deliv
cell
vivo
method
accomplish
middl
includ
chemic
conjug
passeng
strand
cholesterol
bind
sirna
antibodi
fragmentprotamin
fusion
protein
cell
receptormedi
uptak
incorpor
sirna
special
liposom
nanoparticl
express
shrna
precursor
viral
vector
bottom
deliv
sirna
test
small
anim
nonhuman
primat
peopl
applic
sirna
mucos
tissu
lung
use
inhal
exampl
requir
special
deliveri
method
report
rais
possibl
cell
type
tissu
might
actual
amen
system
target
target
tissu
deep
within
bodi
clinic
feasibl
noninvas
strategi
need
devis
direct
sirna
cell
past
year
sever
approach
achiev
impress
therapeut
benefit
follow
intraven
inject
mice
primat
use
reason
dose
sirna
without
appar
limit
toxic
figur
one
approach
involv
coval
coupl
passeng
strand
sirna
cholesterol
facilit
uptak
ubiquit
express
cellsurfac
ldl
receptor
soutschek
et
al
approach
target
sirna
liver
jejunum
fact
rich
vascular
suppli
role
blood
filter
detoxifi
organ
liver
intern
organ
probabl
easiest
target
silenc
cholesterol
transport
protein
apob
cholesterolconjug
chemic
stabil
apob
sirna
reduc
serum
cholesterol
mice
howev
therapeut
effect
requir
high
sirna
dose
mgkg
unlik
applic
human
similarli
impress
decreas
serum
cholesterol
could
achiev
design
cholesterolconjug
stabil
sirna
activ
strand
complementari
endogen
microrna
express
primarili
liver
sirna
design
interfer
abil
microrna
silenc
target
krutzfeldt
et
al
drug
base
sirna
mimic
antagon
endogen
microrna
function
may
valu
treat
cancer
microrna
import
regul
cellular
differenti
goe
awri
tumor
format
croce
calin
hammond
conjug
sirna
small
molecul
either
natur
ligand
cellsurfac
receptor
small
molecul
drug
would
theoret
provid
altern
way
target
specif
subset
cell
bear
specifi
receptor
although
cell
bear
cholesterol
receptor
steer
sirna
specif
cell
type
chemic
conjug
ligand
celltypespecif
receptor
would
like
reduc
necessari
drug
dose
well
limit
toxic
unintend
bystand
cell
anoth
strategi
deliv
sirna
liver
involv
encapsul
sirna
special
liposom
form
use
polyethylen
glycol
reduc
uptak
scaveng
cell
enhanc
time
spent
circul
special
nucleic
acid
particl
stabl
nucleic
acidlipid
particl
snalp
deliv
sirna
effect
liver
organ
reduc
replic
hepat
b
replicon
mice
morrissey
et
al
apob
express
nonhuman
primat
zimmermann
et
al
deliveri
snalp
strategi
develop
protiva
reduc
effect
sirna
dose
mgkgday
practic
therapeut
dose
liposom
lipoplex
nanoparticl
sirna
formul
least
principl
vari
respect
size
lipid
composit
incorpor
target
molecul
direct
sirna
treatment
site
cellspecif
target
strategi
effect
mgkg
sirna
dose
mous
tumor
model
involv
mix
sirna
fusion
protein
compos
target
antibodi
fragment
link
protamin
basic
protein
nucleat
dna
sperm
bind
sirna
charg
song
et
al
fusion
protein
deliv
sirna
exquisit
specif
wide
varieti
cell
includ
primari
hematopoiet
cell
ordinarili
difficult
transfect
even
vitro
fusion
protein
deliv
sirna
hivinfect
lymphocyt
uninfect
cell
song
et
al
activ
leukocyt
rest
leukocyt
peer
p
zhu
shimaoka
jl
unpublish
data
sirna
coval
bound
deliveri
agent
use
deliv
differ
sirna
cocktail
sirna
exampl
system
sirna
deliveri
begin
suggest
deliveri
hurdl
insurmount
approach
work
best
like
depend
target
cell
indic
unmodifi
uncomplex
sirna
short
halflif
blood
minut
limit
use
drug
rapidli
elimin
renal
excret
ratelimit
factor
also
degrad
somewhat
slowli
hr
serum
rnase
inform
halflif
unmodifi
sirna
bodili
fluid
bath
mucos
portal
entri
eye
avail
given
rapid
elimin
dramat
therapeut
effect
unmodifi
sirna
anim
diseas
model
bitko
et
al
pallis
et
al
song
et
al
inde
impress
bode
well
effect
modifi
sirna
drug
improv
pharmacokinet
properti
insid
cell
activ
strand
sirna
incorpor
risc
appear
incred
stabl
silenc
tissu
persist
week
pallis
et
al
song
et
al
zimmermann
et
al
two
factor
seem
control
persist
silencingth
rate
cell
divis
target
cell
sirna
dilut
cell
divis
reduc
sirna
concentr
presenc
target
mrna
within
cell
silenc
sustain
slowli
divid
cell
express
target
mrna
song
et
al
infrequ
dose
may
possibl
nondivid
slowli
divid
tissu
brain
liver
target
cancer
cell
whether
presenc
target
mrna
enhanc
stabil
sirna
requir
investig
need
consid
design
intervent
exampl
sirnabas
microbicid
use
prevent
viral
infect
might
last
longer
sirna
target
host
receptor
gene
rather
viral
gene
plasma
halflif
sirna
extend
substanti
minut
day
sirna
form
complex
molecul
becom
incorpor
particl
bypass
renal
filtrat
cutoff
kda
chemic
modif
avoid
exonucleas
endonucleas
digest
modif
gener
come
price
reduc
intracellular
silenc
effici
presum
rnai
machineri
optim
handl
unmodifi
endogen
rna
unmodifi
activ
strand
stabl
insid
cell
least
target
present
given
nucleas
sensit
sequenc
depend
one
intellig
strategi
minim
amount
chemic
modif
restrict
linkag
residu
suscept
attack
soutschek
et
al
drug
sirna
except
unintend
offtarget
effect
gene
contain
sequenc
imperfect
complementar
may
unintent
silenc
mrna
cleavag
translat
inhibit
jackson
et
al
offtarget
effect
occur
sirna
mimick
microrna
target
recognit
gene
silenc
jackson
et
al
attract
method
minim
offtarget
effect
recent
describ
chemic
modif
second
residu
activ
strand
sirna
key
residu
seed
region
endogen
microrna
activ
may
suppress
unintend
offtarget
effect
without
interf
silenc
target
gene
jackson
et
al
rule
predict
offtarget
gene
regul
still
crude
complet
use
although
sequenc
high
degre
similar
target
blast
search
need
avoid
unintend
offtarget
chang
mrna
survey
use
mrna
microarray
gener
show
offtarget
mrna
reduc
howev
gene
chang
less
may
clinic
signific
difficult
evalu
extent
unintend
chang
protein
express
translat
inhibit
less
effect
silenc
gene
express
mrna
cleavag
hope
offtarget
effect
weak
caus
clinic
problem
inde
encourag
lack
toxic
far
anim
earli
clinic
studi
unlik
microarray
analys
help
screen
modifi
sirna
sequenc
predict
minim
offtarget
effect
clinic
test
like
provid
use
tool
guid
modif
unexplain
toxic
observ
addit
silenc
unintend
target
sirna
could
potenti
caus
problem
trigger
immun
inflammatori
pathway
may
includ
interferon
respons
tolllik
receptor
tlr
pathway
design
recogn
doublestrand
rna
invad
viral
pathogen
sledz
et
al
innat
immun
cell
sound
alarm
viral
invas
need
toler
endogen
microrna
distinguish
foreign
rna
host
rna
interferon
pathway
effici
trigger
doublestrand
rna
less
nucleotid
length
provid
adequ
size
window
sirna
drug
activ
strand
endogen
singlestrand
rna
bind
risc
nucleotid
long
longer
sirna
need
process
dicer
still
nucleotid
cutoff
may
effect
silenc
nucleotid
sirna
possibl
dicer
process
help
incorpor
sirna
risc
kim
et
al
anim
studi
show
sirna
therapeut
benefit
induct
interferonrespons
gene
detect
even
sensit
realtim
rtpcr
assay
activ
tlr
turn
sequenc
specif
prefer
trigger
gurich
sequenc
judg
et
al
candid
sirna
clinic
use
type
research
need
screen
verifi
activ
inflammatori
pathway
number
effect
sirna
gene
gener
larg
exclud
sirna
bind
tlr
like
preclud
silenc
target
gene
addit
avoid
tlractiv
sequenc
chemic
modif
sirna
abrog
silenc
use
block
tlr
activ
sever
strategi
avail
bypass
unintend
immunostimulatori
effect
sirna
drug
potenti
toxic
like
imped
sirna
drug
develop
import
clinic
applic
notabl
treat
viral
infect
cancer
sirna
drug
resist
select
escap
mutat
target
sequenc
viral
replic
cancer
cell
divis
like
develop
may
problem
sirna
type
small
molecul
drug
synonym
mutat
interfer
sirna
recognit
leav
encod
protein
untouch
one
way
around
potenti
problem
design
sirna
target
sequenc
conserv
nucleotid
level
exist
even
highli
variabl
virus
like
hiv
anoth
strategi
use
strand
sirna
target
one
gene
sequenc
includ
drugresist
variant
altern
sirna
cocktail
use
hit
multipl
gene
case
virus
target
viral
gene
host
gene
focus
target
essenti
viral
replic
cell
divis
resist
mutat
like
interfer
underli
fit
viru
cell
whether
drug
resist
develop
readili
sirna
type
drug
hard
predict
without
clinic
studi
resist
prove
clinic
problem
one
import
advantag
sirna
drug
rel
eas
compar
small
molecul
drug
resist
overcom
simpl
chang
sirna
sequenc
strategi
prevent
anticip
drug
resist
also
lead
develop
drug
suitabl
treat
divers
viral
strain
cancer
variant
interf
endogen
microrna
potenti
caus
toxic
sirna
drug
introduc
exogen
sirna
cell
interfer
process
function
endogen
microrna
copious
express
micrornalik
shrna
either
use
viru
lu
cullen
gene
therapi
vector
grimm
et
al
interfer
endogen
microrna
nuclear
export
exportin
although
sirna
drug
introduc
directli
cytoplasm
compet
microrna
stage
larg
intracellular
sirna
concentr
might
compet
limit
amount
dicer
longer
sirna
precursor
drug
risc
consider
might
set
limit
number
differ
sirna
could
incorpor
drug
cocktail
catalyt
natur
mrna
cleavag
sirna
risc
recycl
cleav
mani
mrna
work
advantag
sirna
drug
fact
may
take
sirna
moleculescel
silenc
gene
express
effici
rough
estim
deriv
frequenc
individu
endogen
microrna
cell
quantit
inform
rel
number
dicer
risc
molecul
endogen
microrna
differ
cell
togeth
inform
number
sirna
requir
effici
gene
silenc
would
help
anticip
whether
toxic
might
issu
slim
hint
sirna
therapeut
phase
studi
intraocular
inject
sirna
target
vegf
pathway
treat
agerel
macular
degener
studi
result
suggest
high
concentr
sirna
might
less
effect
lower
concentr
number
subject
treat
dose
small
draw
conclus
although
mani
potenti
hurdl
stand
way
har
rnai
therapi
seem
surmount
cautiou
optim
order
although
anticip
problem
seem
solvabl
often
unanticip
problem
sidetrack
drug
develop
